Literature DB >> 24818173

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.

L Alexis Hoeferlin1, Charles E Chalfant1, Margaret A Park1.   

Abstract

While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: "Triple negative" and ErbB2-overexpressing, are discussed in this review.

Entities:  

Keywords:  Breast Cancer; ErbB2; Estrogen receptor; Resistance; Triple negative

Year:  2013        PMID： 24818173      PMCID： PMC4012677     

Source DB:  PubMed          Journal:  J Surg Sci        ISSN： 2333-4703


  39 in total

1.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

Authors:  H J Burstein; I Kuter; S M Campos; R S Gelman; L Tribou; L M Parker; J Manola; J Younger; U Matulonis; C A Bunnell; A H Partridge; P G Richardson; K Clarke; L N Shulman; E P Winer
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

Review 2.  Recent advances in novel targeted therapies for HER2-positive breast cancer.

Authors:  Conleth G Murphy; Patrick G Morris
Journal:  Anticancer Drugs       Date:  2012-09       Impact factor: 2.248

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Authors:  Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves
Journal:  Lancet       Date:  2011-03-02       Impact factor: 79.321

Review 5.  Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.

Authors:  Edith A Perez; Tejal Patel; Alvaro Moreno-Aspitia
Journal:  Breast Cancer Res Treat       Date:  2010-03-13       Impact factor: 4.872

6.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Authors:  SaeGwang Park; Zhujun Jiang; Eric D Mortenson; Liufu Deng; Olga Radkevich-Brown; Xuanming Yang; Husain Sattar; Yang Wang; Nicholas K Brown; Mark Greene; Yang Liu; Jie Tang; Shengdian Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

7.  Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.

Authors:  Gloria Fuentes; Maurizio Scaltriti; José Baselga; Chandra S Verma
Journal:  Breast Cancer Res       Date:  2011-05-22       Impact factor: 6.466

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

Authors:  José Baselga; Patricia Gómez; Richard Greil; Sofia Braga; Miguel A Climent; Andrew M Wardley; Bella Kaufman; Salomon M Stemmer; António Pêgo; Arlene Chan; Jean-Charles Goeminne; Marie-Pascale Graas; M John Kennedy; Eva Maria Ciruelos Gil; Andreas Schneeweiss; Angela Zubel; Jutta Groos; Helena Melezínková; Ahmad Awada
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

10.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Authors:  Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard Pietras; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2004-05-19       Impact factor: 13.506
View more
  9 in total

1.  Welcome to the Journal of Surgery and Science!

Authors:  Kazuaki Takabe
Journal:  J Surg Sci       Date:  2013-12

2.  Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen.

Authors:  Li Yin; Xiaohua Pan; Xin-Tian Zhang; Yu-Ming Guo; Zhao-Yi Wang; Yaoqin Gong; Molin Wang
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

3.  Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases.

Authors:  Dana El-Chami; Maria Al Haddad; Ralph Abi-Habib; Mirvat El-Sibai
Journal:  Oncol Lett       Date:  2020-12-31       Impact factor: 2.967

4.  Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.

Authors:  Worapol Ngamcherdtrakul; Jingga Morry; Shenda Gu; David J Castro; Shaun M Goodyear; Thanapon Sangvanich; Moataz M Reda; Richard Lee; Samuel A Mihelic; Brandon L Beckman; Zhi Hu; Joe W Gray; Wassana Yantasee
Journal:  Adv Funct Mater       Date:  2015-05-13       Impact factor: 18.808

5.  Blockade of exosome release alters HER2 trafficking to the plasma membrane and gives a boost to Trastuzumab.

Authors:  Leila Asef-Kabiri; Hamzeh Sarvnaz; Alireza Ghanavatinejad; Reza Hosseini; Fatemeh Rezayat; Nahid Eskandari; Mohammad Esmaeil Akbari
Journal:  Clin Transl Oncol       Date:  2022-08-26       Impact factor: 3.340

6.  Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.

Authors:  Kitti Andreidesz; Balazs Koszegi; Dominika Kovacs; Viola Bagone Vantus; Ferenc Gallyas; Krisztina Kovacs
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

Review 7.  MicroRNA-1: Diverse role of a small player in multiple cancers.

Authors:  Parvez Khan; Nivetha Sarah Ebenezer; Jawed Akhtar Siddiqui; Shailendra Kumar Maurya; Imayavaramban Lakshmanan; Ravi Salgia; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Semin Cell Dev Biol       Date:  2021-05-24       Impact factor: 7.727

Review 8.  Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach.

Authors:  Chris Vi; Giovanni Mandarano; Sarah Shigdar
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

Review 9.  Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.

Authors:  Christopher Montemagno; Gilles Pagès
Journal:  Cancers (Basel)       Date:  2020-03-29       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.